- Home
- PRLD vs BCAB Comparison
PRLD vs BCAB Comparison
Compare PRLD & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRLD | BCAB |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 71.6M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRLD | BCAB |
|---|---|---|
| Price | $2.12 | $0.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $4.00 | $1.00 |
| AVG Volume (30 Days) | 470.6K | ★ 1.3M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 250.00 | N/A |
| 52 Week Low | $0.61 | $0.24 |
| 52 Week High | $4.22 | $1.43 |
Technical Indicators
Market Signals| Indicator | PRLD | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 45.49 |
| Support Level | $1.60 | $0.74 |
| Resistance Level | $2.17 | $0.83 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 93.71 | 9.86 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.